Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.
Mundipharma will be able to market Prestige BioPharma’s Tuznue (trastuzumab) biosimilar exclusively in “selected European countries” including Austria, Denmark, Finland, France, Norway, Portugal, Spain, Sweden and Switzerland upon approval, according to the terms of an agreement between the two companies.
Prestige had in late June announced positive results from a Phase III trial of the HD201 trastuzumab biosimilar candidate that...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
